Fred Hutchinson Cancer Center

Blaze Bioscience, Inc.

University of Washington

Presage Biosciences, Inc.

Fred Hutchinson Cancer Research Center

Fred Hutchinson Cancer Research Foundation

James M Olson

Mandana Veiseh

S Bahram Bahrami

Christopher Mehlin

Colin Correnti

Roland K Strong

Natalie Winblade Nairn

Andrew David Strand

Emily June Girard

Omid Veiseh

Miqin Zhang

Richard Glen Ellenbogen

Stephen J Tapscott

Raymond W Sze

Philip Bradley

Zachary Crook

Soheil Meshinchi

Ashok Bandaranayake

Patrik Gabikian

S-Bahram Bahrami

Gene Gregory Hopping

Mi-Youn Brusniak

Andrew James Mhyre

Chunfeng Yin

Mesothelin (MSLN) is expressed on pancreatic cancers, ovarian cancers and mesotheliomas. The present disclosure provides antigen-binding molecules, including anti-MSLN antibodies, and bispecific antigen-binding molecules that bind to both MSLN and a T cell antigen (e.g., CD3) and activate T cells in the presence of MSLN-expressing tumor cells. The antigen-binding molecules of this disclosure are useful for the treatment of diseases and disorders in which a MSLN-targeted immune response is desired and/or therapeutically beneficial. For example, the antigen-binding molecules of the present disclosure are useful for the treatment of various cancers, including pancreatic cancer, ovarian cancer and mesotheliomas.

Anti-mesothelin antigen-binding molecules and uses thereof

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.

Cartilage-homing peptides

Described herein are peptides and variants and mutants thereof capable of interacting with TEAD, disrupting the HIPPO pathway, or modulating the activity or function of TEAD interactions in a cell. Pharmaceutical compositions and uses of peptides, as well as methods of designing and manufacturing such peptides, to treat cancer, tumor, or any other disease/condition associated with a dysregulated HIPPO pathway or uncontrolled cell growth are also described herein.

Peptide compositions and methods of use thereof for disrupting TEAD interactions

Chlorotoxin variants, chlorotoxin variant conjugates, compositions that include the chlorotoxin variants or conjugates, and methods for using the chlorotoxin variants, conjugates, and compositions.

Chlorotoxin variants, conjugates, and methods for their use

Methods and systems for producing fusion proteins and peptides are disclosed. Fusion proteins and peptides created using the methods are also provided. Also provided are methods of using the fusion proteins and peptides produced according to the present disclosure.

Lipocalin fusion partners

A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to deliver a substantially equal amount of fluid at any given location along its length. A driver is coupled to the actuators to selectively control the rate, volume, and direction of flow of fluid through the needles. The device can simultaneously deliver a plurality of fluid agents along respective axes in solid tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue, and based on the evaluation, candidate agents selected or deselected for clinical trials or therapy, and subjects selected or deselected for clinical trials or therapeutic treatment.

Needle array assembly and method for delivering therapeutic agents

A chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate.

Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer

Growing community of inventors

S. Seattle, WA, United States of America

James M Olson